What should I look for in AOD-9604 sourcing and quality?

Acceptable AOD-9604 certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 1815.1 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What class of compound is AOD-9604?

AOD-9604 is classified as a GH fragment. Within this class, alternative names and analogues include hGH fragment 176-191, AOD9604. The class-level pharmacology shapes both the clinical applications and the safety profile; the female physiology literature treats AOD-9604 alongside its class peers when evaluating relative merits.

How does AOD-9604 interact with female hormonal cycling?

Cyclical hormone background influences how AOD-9604 is distributed, metabolised, and felt. Even where the compound's pharmacology is not directly hormonal, response often varies across follicular and luteal phases. Premenopausal users should track by cycle phase for 1–2 cycles before settling on a fixed schedule; perimenopausal users benefit from integration with HRT where indicated.

Home/ Compounds/ AOD-9604

AOD-9604

Women's Health

Women's-health applications of AOD-9604 require explicit attention to cyclical hormonal context, contraceptive and pregnancy considerations, and — for users in perimenopause or postmenopause — integration with HRT. Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. Dosing at 300-500 mcg 1x daily am via subq/oral (capsule, lower bioavailability) with cycle-phase-aware tracking is the standard protocol for premenopausal users.

Female Physiology Applications

Libido (Female)Endometriosis SupportCycle SupportBody Composition (Female)Bone Density

Key Takeaways

Female-physiology lens: AOD-9604 response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 300-500 mcg 1x daily am via subq/oral (capsule, lower bioavailability); cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Mimics the C-terminal of human growth hormone (residues 176-191) to stimulate lipolysis and inhibit lipogenesis via β3-adrenergic-like signalling, without engaging the GH receptor or driving IGF-1 elevation. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. AOD-9604's contribution to each varies; the subsections below work through these in turn.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. AOD-9604's effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Cyclical and hormonal context

Female physiology is cyclical in a way that male physiology is not, and AOD-9604's effects often vary across follicular versus luteal phase. Even where the compound's pharmacology is not directly hormonal, the cyclical hormone background influences how it is metabolised, distributed, and felt. Pre-menopausal users should expect to track response by cycle phase for one or two cycles before settling on a fixed schedule.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, AOD-9604 is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Female Physiology Applications

Cycle Support

For cycle support in female users, AOD-9604 is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Libido (Female)

In the perimenopausal window, AOD-9604 for libido (female) produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Skin Health

Skin Health is one of the dimensions on which women track AOD-9604 response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

PCOS Support

For pcos support in female users, AOD-9604 is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	300-500 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	180-500 mcg	4–6 weeks initial cycle
Women's Health focus	SubQ	300-500 mcg	1x daily AM
Maintenance phase	SubQ	210-500 mcg	Ongoing with periodic pauses

Dose timing for AOD-9604 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

AOD-9604 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

AOD-9604 + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with AOD-9604's mechanism in female physiology protocols.
AOD-9604 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with AOD-9604's mechanism in female physiology protocols.
AOD-9604 + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with AOD-9604's mechanism in female physiology protocols.
AOD-9604 + Epithalon: Identified by Khavinson in St. Pairs naturally with AOD-9604's mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list (verify annually) FDA: Unapproved (Research Only) Research: Phase IIb completed; not commercialised

No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data).

Lens-specific safety considerations for female physiology use of AOD-9604: No significant elevation of IGF-1, glucose, or insulin in trials. Generally well tolerated. Pregnancy/lactation: avoid (no data). Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Effects of an oral lipolytic peptide (AOD9604) on body composition in obese subjects

PMID 12972433

Supporting

AOD9604 and obesity: clinical findings

PMID 19077115

AOD-9604 vs Related Peptides

Compound	Profile	Onset	Best For
AOD-9604	GH fragment	~30 min IV; longer SubQ	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

Is AOD-9604 appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

Can I use AOD-9604 alongside HRT?

Yes, in most cases. Integration with HRT — estrogen, progesterone, sometimes testosterone — is additive rather than competitive for most peptide compounds. Coordinating with a HRT-prescribing physician on dose timing and monitoring is the standard approach.

Does AOD-9604 affect bone density?

Several peptide compounds have measurable effects on bone-remodelling markers, particularly relevant for post-menopausal users. Where AOD-9604 specifically engages this pathway, paired pre-post DEXA or bone-marker tracking provides the cleanest evaluation. For most compounds the bone effect is secondary and develops over months.

How does AOD-9604's half-life affect dosing?

AOD-9604 has a plasma half-life of ~30 min IV; longer SubQ, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x daily am dosing at 300-500 mcg per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

Should I cycle AOD-9604?

Standard cycle for AOD-9604 is 8–12 weeks of 1x daily am 300-500 mcg dosing via subq/oral (capsule, lower bioavailability), followed by a 4 week complete off-period. The off-period is calibrated to AOD-9604's ~30 min IV; longer SubQ half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Clinical Protocol

Start a AOD-9604 Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified AOD-9604 and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: 1815.1 Da
Sequence length: 16 aa
Half-life: ~30 min IV; longer SubQ
WADA: Not on prohibited list (verify annually)
FDA: Unapproved (Research Only)
Research: Phase IIb completed; not commercialised

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for AOD-9604 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for AOD-9604

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised